GSK Pakistan Delivers Strong Financial Performance in 2025
GlaxoSmithKline Pakistan Limited (GSK Pakistan) reported a significant improvement in its financial performance during 2025, supported by higher revenue, stronger profitability and continued investment in its pharmaceutical manufacturing and healthcare operations.
According to the company’s Annual Report 2025, net revenue from contracts with customers increased to Rs65.9 billion, compared with Rs61.2 billion in 2024. Gross profit also rose substantially to Rs24.4 billion, up from Rs15.4 billion a year earlier. Operating profit reached Rs16.9 billion, compared with Rs10.8 billion in 2024.
The improvement extended to the bottom line. GSK Pakistan recorded profit after taxation of Rs10.0 billion in 2025, compared with Rs6.5 billion in 2024. Earnings per share increased to Rs31.48 from Rs20.52, while return on equity improved from 23.1% to 29.8%.
Stronger Cash Generation
The company also reported improved operating cash flow. Cash generated from operating activities increased to Rs8.66 billion in 2025, compared with Rs5.06 billion in the previous year. Cash and cash equivalents at year-end stood at Rs8.59 billion, compared with Rs6.51 billion in 2024.
GSK Pakistan’s shareholder returns also increased. The annual report shows cash dividends of approximately Rs5.41 billion during 2025, compared with Rs3.18 billion in 2024. Cash dividend per share stood at Rs17, compared with Rs10 a year earlier.
Continued Manufacturing Presence in Pakistan
GSK Pakistan maintains a substantial manufacturing footprint in Karachi, with facilities at F-268 SITE, West Wharf and Korangi. The company says its Global Supply Chain operations manufacture around 370 million packs annually across these facilities.
The F-268 SITE facility produces medicines across liquids, penicillin and tablets, while the West Wharf facility manufactures dermatology products and other medicines. The Korangi facility includes dedicated capabilities for cephalosporins, sterile liquid ampoules, eye drops and tablets.
Focus on Medicines, Vaccines and Innovation
GSK Pakistan’s portfolio covers several therapy areas, including anti-infectives, dermatology, analgesics and vaccines. Its key brands include Augmentin, Amoxil, Velosef, Dermovate, Clobevate, Betnovate and Calpol. The company also launched Shingrix in Pakistan during 2025, expanding its presence in adult vaccination.
At the global level, GSK reported £6.6 billion in research and development investment in 2025, alongside 58 vaccines and medicines in its pipeline and 17 assets in Phase III or registration. The group also reported turnover of £32.7 billion.
Overall, GSK Pakistan’s 2025 annual report highlights a year of stronger revenue, profitability and cash generation, alongside continued manufacturing activity and a focus on medicines, vaccines and healthcare innovation. The company’s financial results show a substantial improvement compared with 2024, while its operations remain closely connected to Pakistan’s pharmaceutical manufacturing and healthcare market.
